Adaptive Biotechnologies (ADPT) Non-Current Deffered Revenue (2018 - 2026)

Adaptive Biotechnologies has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $807000.0 in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 96.75% year-over-year to $807000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $807000.0 (down 96.75% YoY) and the FY2025 annual result came in at $1.0 million, down 96.31% from the prior year.
• Non-Current Deffered Revenue retreated to $807000.0 in Q1 2026 per ADPT's latest filing, from $1.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $84.9 million in Q1 2022 and troughed at $807000.0 in Q1 2026.
• A 5-year average of $39.4 million and a median of $44.2 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2024 and 2026: Non-Current Deffered Revenue retreated 18.08% in 2024, then tumbled 96.75% in 2026.
• Over 5 years, Non-Current Deffered Revenue stood at $58.6 million in 2022, then slipped by 23.56% to $44.8 million in 2023, then slumped by 39.15% to $27.3 million in 2024, then plunged by 96.31% to $1.0 million in 2025, then dropped by 19.78% to $807000.0 in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $807000.0, $1.0 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.